Philip Vickers

Chief Executive Officer at Faze Medicines

Philip Vickers

Philip Vickers

Chief Executive Officer at Faze Medicines

Overview
Career Highlights

Resolvyx Pharmaceuticals, Inc.
Faze Medicines
Northern Biologics, Inc.

RelSci Relationships

335

Number of Boards

7

Birthday

1960

Age

61

Relationships
RelSci Relationships are individuals Philip Vickers likely has professional access to. A relationship does not necessarily indicate a personal connection.

Advisor at Celtic Pharma Management LP

Relationship likelihood: Strong

President & Chief Executive Officer at Revance Therapeutics, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer at Pfizer Global Research & Development

Relationship likelihood: Strong

Former Chief Operating Officer at Warp Drive Bio, Inc.

Relationship likelihood: Strong

Co-Founder at Juvenescence Ltd.

Relationship likelihood: Strong

Former Associate Director & Head-Molecular Biology at Pfizer Global Research & Development

Relationship likelihood: Strong

Founder & Chief Financial Officer at Arvelle Therapeutics International GmbH

Relationship likelihood: Strong

Former Senior Director, Global Research & Development at Pfizer Global Research & Development

Relationship likelihood: Strong

Chief Financial & Accounting Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Former Chief Human Resources Officer & Executive Vice President at Shire Plc

Relationship likelihood: Strong

Paths to Philip Vickers
Potential Connections via
Relationship Science
You
Philip Vickers
Chief Executive Officer at Faze Medicines
Education

Established in 1827, the University of Toronto has one of the strongest research and teaching faculties in North America, presenting top students at all levels with an intellectual environment unmatched in depth and breadth on any other Canadian campus. With more than 82,000* students across three campuses (St. George, Mississauga and Scarborough) and over 500,000 alumni active in every region of the world, U of T's influence is felt in every area of human endeavour.

Established with a clear vision to excel in teaching, research, innovation and engagement, Salford Business School enjoys an excellent national and international reputation for its courses, teaching quality and the progression of students into responsible positions across a variety of industries. Their emphasis of combining a highly contemporary curriculum with a range of professional development opportunities provides a mix of academic and hands on development.

Career History
Chief Executive Officer
2021 - Current

Faze Medicines is a biotechnology company harnessing the groundbreaking new science of biomolecular condensates to create medical breakthroughs.

Vice President & Head-Pfizer Research Technology Center
Tenure Unconfirmed
President & Chief Executive Officer
2017 - 2021

Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada.

Boards & Committees
Director
Prior

Neusentis Ltd. engages in other business support service activities. The company was founded on October 2, 1997 and is headquartered in Sandwich, the United Kingdom.

Political Donations
$250
2010

Secretary, Chief Legal Officer & Executive Vice President at Rimini Street, Inc.

Transactions
Details Hidden

Resolvyx Pharmaceuticals, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Philip Vickers. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Philip Vickers's profile does not indicate a business or promotional relationship of any kind between RelSci and Philip Vickers.